News

Trial Finds New Drug Can Delay Type 1 Diabetes

The clinical trial involving Australian researchers show a drug that targets the immune system can delay type 1 diabetes (T1D) by two years in children and adults at high risk.

Facts and figures:

The study published in the New England Journal of Medicine ran for five years and involved 76 children and young adults at very high risk of developing type 1 diabetes.

‘Teplizumab’ delayed the onset of diabetes by two years.

The Royal Melbourne Hospital is one of 28 sites that participated in the study conducted by TrialNet, the largest clinical trial network ever assembled to discover ways to delay and prevent type 1 diabetes.

This trial is being run in conjunction with several others that will likely have major changes for diabetes worldwide.

Ask the expert:

The Royal Melbourne Hospital’s Associate Professor John Wentworth

“We have known for over 3 decades how to identify children who are destined to develop type 1 diabetes. Now, for the first time, we have something that will improve their prospects and delay the need to start insulin injections to control blood sugar levels.”

“These results are incredibly encouraging.”

The details:

For more information about current Australian clinical trials can be found at www.diabetesresearchcentre.org.au/clinical-trials

More information about TrialNet can be found at www.trialnet.org

Share this...
Share on LinkedInShare on FacebookTweet about this on TwitterEmail this to someone

Leave a Comment

Your email address will not be published.

You may also like

Newsletter Signup